Uchiyama T, Sugiyama T, Quan Y S, Kotani A, Okada N, Fujita T, Muranishi S, Yamamoto A
Department of Biopharmaceutics, Kyoto Pharmaceutical University, Japan.
J Pharm Pharmacol. 1999 Nov;51(11):1241-50. doi: 10.1211/0022357991776976.
We have examined the in-vitro permeability characteristics of insulin in the presence of various absorption enhancers across rat intestinal membranes and have assessed the intestinal toxicity of the enhancers using an in-vitro Ussing chamber method. The absorption enhancing mechanism of n-lauryl-beta-D-maltopyranoside was studied also. The permeability of insulin across the intestinal membranes was low in the absence of absorption enhancers. However, the permeability was improved in the presence of enhancers such as sodium glycocholate and sodium deoxycholate in the jejunum, and sodium glycocholate, sodium deoxycholate, n-lauryl-beta-D-maltopyranoside, sodium caprate and ethylenediaminetetraacetic acid (EDTA) in the colon. Overall, the absorption enhancing effects were greater on the colonic membrane than on the jejunal membrane. The intestinal membrane toxicity of these enhancers was characterized using the release of cytosolic lactate dehydrogenase from the colonic membrane. A marked increase in the release of lactate dehydrogenase was observed in the presence of sodium deoxycholate and EDTA. The release of lactate dehydrogenase in the presence of these absorption enhancers was similar to that seen with sodium dodecyl sulphate (SDS), used as a positive control, indicating high toxicity of these enhancers to the intestinal membrane. In contrast, sodium glycocholate and sodium caprate caused minor releases of lactate dehydrogenase, similar to control levels, suggesting low toxicity. In addition, the amount of lactate dehydrogenase in the presence of n-lauryl-beta-D-maltopyranoside was much less than that seen with sodium deoxycholate, EDTA and SDS. Therefore, sodium glycocholate, sodium caprate and n-lauryl-beta-D-maltopyranoside are useful absorption enhancers due to their high absorption enhancing effects and low intestinal toxicity. To investigate the absorption enhancing mechanisms of n-lauryl-beta-D-maltopyranoside, the transepithelial electrical resistance (TEER), voltage clamp experiments and the circular dichroism spectra were studied. n-Lauryl-beta-D-maltopyranoside decreased the TEER values in a dose-dependent manner, suggesting that the enhancer may open the tight junctions of the epithelium, thereby increasing the permeability of insulin via a paracellular pathway. This speculation was supported by the findings that 20 mM n-lauryl-beta-D-maltopyranoside produced a greater increase in the paracellular flux rate than in the transcellular flux rate by the voltage clamp studies. Evaluating the circular dichroism spectra we found that insulin oligomers were not dissociated to monomers by the addition of n-lauryl-beta-D-maltopyranoside, but dissociation did occur with the addition of sodium glycocholate. Thus, the dissociation of insulin was not a major factor in the absorption enhancing effect of n-lauryl-beta-D-maltopyranoside. These findings provide basic information to select the optimal enhancer for the intestinal delivery of peptide and protein drugs including insulin.
我们研究了在多种吸收促进剂存在的情况下胰岛素跨大鼠肠膜的体外渗透特性,并使用体外尤斯灌流小室法评估了这些促进剂的肠道毒性。同时还研究了正十二烷基-β-D-麦芽糖苷的吸收增强机制。在没有吸收促进剂的情况下,胰岛素跨肠膜的渗透性较低。然而,在空肠中存在甘氨胆酸钠和脱氧胆酸钠等促进剂时,渗透性得到改善;在结肠中,甘氨胆酸钠、脱氧胆酸钠、正十二烷基-β-D-麦芽糖苷、癸酸钠和乙二胺四乙酸(EDTA)存在时,渗透性也得到改善。总体而言,吸收增强作用在结肠膜上比在空肠膜上更大。使用结肠膜中细胞溶质乳酸脱氢酶的释放来表征这些促进剂的肠膜毒性。在脱氧胆酸钠和EDTA存在时,观察到乳酸脱氢酶的释放显著增加。在这些吸收促进剂存在时乳酸脱氢酶的释放与用作阳性对照的十二烷基硫酸钠(SDS)相似,表明这些促进剂对肠膜具有高毒性。相比之下,甘氨胆酸钠和癸酸钠导致乳酸脱氢酶的释放较小,与对照水平相似,表明毒性较低。此外,在正十二烷基-β-D-麦芽糖苷存在时乳酸脱氢酶的量远低于在脱氧胆酸钠、EDTA和SDS存在时的量。因此,甘氨胆酸钠、癸酸钠和正十二烷基-β-D-麦芽糖苷因其高吸收增强作用和低肠道毒性而成为有用的吸收促进剂。为了研究正十二烷基-β-D-麦芽糖苷的吸收增强机制,研究了跨上皮电阻(TEER)、电压钳实验和圆二色光谱。正十二烷基-β-D-麦芽糖苷以剂量依赖性方式降低TEER值,表明该促进剂可能打开上皮细胞的紧密连接,从而通过细胞旁途径增加胰岛素渗透性。电压钳研究发现20 mM正十二烷基-β-D-麦芽糖苷导致细胞旁通量率的增加大于跨细胞通量率的增加,这一发现支持了上述推测。通过评估圆二色光谱,我们发现添加正十二烷基-β-D-麦芽糖苷不会使胰岛素寡聚体解离为单体,但添加甘氨胆酸钠时会发生解离。因此,胰岛素的解离不是正十二烷基-β-D-麦芽糖苷吸收增强作用的主要因素。这些发现为选择用于包括胰岛素在内的肽和蛋白质药物肠道递送的最佳促进剂提供了基础信息。
Bioeng Transl Med. 2022-5-31
Pharmaceuticals (Basel). 2022-12-19
Pharm Res. 2017-7-18